What is the difference between Victoza and Saxenda?

Both contain liraglutide but at different doses and for different indications. Victoza (1.2-1.8 mg) is for type 2 diabetes. Saxenda (3.0 mg) is for weight management. They should not be used together.

How does liraglutide compare to semaglutide?

Semaglutide is a newer GLP-1 agonist that generally produces greater weight loss (15% vs 8%) and is dosed weekly rather than daily. However, liraglutide has more long-term safety data and was the first GLP-1 agonist approved for obesity.

Is liraglutide FDA approved?

Yes. Liraglutide is FDA-approved as Victoza for type 2 diabetes (2010) and as Saxenda for chronic weight management (2014). It has one of the longest track records among GLP-1 agonists.

Content reviewed by clinical research staff

Last reviewed: March 2026Sources: PubMed, FDA, WADA Prohibited List

Evidence graded using the PeptideScholar A-D system

Liraglutide

AFDA Approved

GLP-1 receptor agonist · 31 amino acids · Brand: Victoza, Saxenda

FDA ApprovedPrescription Required

Liraglutide is a GLP-1 receptor agonist approved by the FDA for type 2 diabetes (Victoza) and chronic weight management (Saxenda). It was the first GLP-1 agonist approved specifically for obesity.

Mechanism of Action

Mimics endogenous GLP-1, activating GLP-1 receptors to enhance insulin secretion, suppress glucagon, slow gastric emptying, and reduce appetite through hypothalamic signaling. Has 97% amino acid sequence homology with human GLP-1.

Benefits

FDA-approved for both diabetes and obesity
Proven cardiovascular risk reduction (LEADER trial)
Extensive long-term safety data (10+ years)
Daily dosing allows flexible titration

Not Medical Advice — Research-Reported Information Only

This content is for informational purposes only and does not constitute medical advice.

Liraglutide — Dosing in Published Research

Reported Routes: Subcutaneous injection

Victoza: titrated from 0.6 mg to 1.2-1.8 mg SC daily. Saxenda: titrated from 0.6 mg to 3.0 mg SC daily over 5 weeks.

The dosing information above is sourced from published research literature and clinical trials. These are not recommendations. Individual responses vary. Always consult a healthcare provider before considering any peptide-based therapy.

Side Effects

Nausea and vomiting (most common during titration)
Diarrhea or constipation
Pancreatitis risk (rare)
Gallbladder disorders
Injection site reactions

Ready to Discuss Liraglutide with a Doctor?

Liraglutide is FDA-approved and available by prescription. Licensed telehealth providers can evaluate if it's right for you.

Find a Prescribing Provider

Telehealth consultations available in most states

FDA ApprovedBoard-Certified DoctorsPrescription if Appropriate

PeptideScholar may receive compensation from provider referrals. This does not influence our editorial content.

Research & Evidence

RCTNew England Journal of Medicine, 2016

Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes (LEADER)

Liraglutide reduced major adverse cardiovascular events by 13% vs placebo in type 2 diabetes patients at high cardiovascular risk

PMID: 28215665

RCTNew England Journal of Medicine, 2015

Liraglutide 3.0 mg for Weight Management (SCALE Obesity)

Liraglutide 3.0 mg produced 8.0% mean body weight loss vs 2.6% with placebo over 56 weeks in 3,731 adults

PMID: 25998169

Compare Liraglutide With

Liraglutide vs Semaglutide

Liraglutide vs Tirzepatide

References

1. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes (LEADER). New England Journal of Medicine, 2016. “Liraglutide reduced major adverse cardiovascular events by 13% vs placebo in type 2 diabetes patients at high cardiovascular risk” [PMID: 28215665]
2. Liraglutide 3.0 mg for Weight Management (SCALE Obesity). New England Journal of Medicine, 2015. “Liraglutide 3.0 mg produced 8.0% mean body weight loss vs 2.6% with placebo over 56 weeks in 3,731 adults” [PMID: 25998169]

Recommended Resources

The Peptide Protocols Handbook

Evidence-based reference guide covering mechanisms, research, and clinical applications.

View on Amazon

Third-Party Peptide Testing

Independent lab analysis to verify peptide purity and authenticity.

Learn More

Links may be affiliate links. See our disclosure.

Liraglutide FAQ

Medical Disclaimer

This content is for informational and educational purposes only and does not constitute medical advice, diagnosis, or treatment recommendations.

Always consult a qualified healthcare provider before starting, stopping, or modifying any treatment. Do not disregard professional medical advice based on information found on this site.

No claims of therapeutic efficacy are made for substances that are not FDA-approved for the discussed indications. Research citations reflect published findings and do not imply endorsement.

Related Peptides

Semaglutide

Weight LossFDA Approved

Semaglutide is a GLP-1 receptor agonist approved by the FDA for type 2 diabetes ...

Evidence Level AView Details

Tirzepatide

Weight LossFDA Approved

Tirzepatide is the first dual GIP and GLP-1 receptor agonist, approved by the FD...

Evidence Level AView Details

Get Peptide Research Updates

Weekly evidence summaries and regulatory alerts.

No spam. Unsubscribe anytime.